Biosimilar Products for Research Use

AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.

Investigating the biological effects of a drug or doing proof of concept assay development, requires a source of the drug. Typically, it is difficult to obtain original pharmaceutical grade biotherapeutic drugs for research use, rather than a clinical application. Consequently, biological compounds almost identical to a reference biologic drug (biosimilars) that have been approved by governmental regulatory authorities for medical treatment are vital research tools.

To develop an effective biologic drug, it is important to synthesize a reference antibody. A reference antibody can greatly facilitate the downstream development of a new biologic drug and can help identify critical cell lines, reagents and performance characteristics. AMSBIO's new range of biosimilar antibodies for research use avoid the need to source an expensive therapeutic product and enable fast and inexpensive assay development.

One of the main challenges in analyzing the impact of biosimilars is obtaining a validated positive control for in-situ analysis. For this task - FFPE cytosections of HEK293T cell pellet that over-express targeted proteins are available from AMSBIO. These cells are obtained by transfection of a sequenced verified cDNA clones transfected into HEK293T cells and the expression is verified by western blot and IHC analysis.

For further information on biosimilar antibodies for research use and validated positive controls to analyze their impact please visit https://www.amsbio.com/biosimilars/ or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.   


Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

Media Contact Information: